Stock Ratings / Health Care / IMNN / dividends

TRAW (38) AZTR (41) APUS (43) XBIO (47) ⌘ Pro Terminal →

Imunon Inc. (IMNN) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.83 +0.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Imunon Inc. (IMNN) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $4.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMNN)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMNN)

✓Walkthrough of IMNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.67%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.84H $1.00L $0.83C $0.83VOL 131.6K

RES: $1.42SUP: $0.72SMA50: $1.31SMA200: $2.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMNN Butterfly Map → + Track IMNN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMNN)

Health Care Rank #598 of 1016 ⚔️ TRAW vs IMNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMNN vs. TRAW, AZTR, APUS, XBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Imunon Inc. (IMNN) ranks #598 by composite RQD confidence (42/100, grade D-) and #952 by equity capitalization ($4.7M). Within this direct 5-issuer industry benchmark cohort, IMNN leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. XBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with IMNN at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMNN ACTIVE Imunon Inc.	D-	42/100	—	—	-35.0%	+0.35%	$4.7M	Benchmark Subject
TRAW Traws Pharma Inc.	D-	38/100	—	—	-35.0%	-16.34%	$4.6M	/traw-vs-imnn →
AZTR Azitra Inc	D-	41/100	—	—	-35.0%	-16.31%	$4.6M	/aztr-vs-imnn →
APUS Apimeds Pharmaceuticals US Inc.	D-	43/100	—	—	-6.2%	+4.56%	$5.0M	/apus-vs-imnn →
XBIO Xenetic Biosciences Inc.	D	47/100	—	—	-30.3%	+0.95%	$5.0M	/xbio-vs-imnn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000749647

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Imunon Inc. (IMNN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $14.5M, operating cash flow of -$13.9M, and free cash flow of -$14.2M (+24.9% YoY). On the balance sheet, IMNN closed FY2025 with $12.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$14.5M	-$13.9M	-$14.2M	$12.3M	—
FY2024 (FY)	2024-12-31	$0	-$18.6M	-$18.9M	-$18.9M	$9.7M	—
FY2023 (FY)	2023-12-31	$0	-$19.5M	-$19.0M	-$19.0M	—	—

3. IMNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Imunon Inc. (NASDAQ: IMNN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.83 (+0.35% 1D, market cap $4.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IMNN ranks #598 in composite RQD confidence.

How does IMNN compare to TRAW and AZTR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNN carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TRAW (Traws Pharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $4.6M) and AZTR (Azitra Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $4.6M). Among the 5-stock peer group, IMNN leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMNN?

Per IMNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000749647), Imunon Inc. generated $0 in revenue, $14.5M in net income, and -$14.2M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMNN trading relative to its 50-day, 200-day, and 52-week technical levels?

IMNN last traded at $0.83 (+0.35% on volume of 211,777 shares), positioning the stock -36.64% below its 50-day simple moving average ($1.31) and -62.95% below its 200-day simple moving average ($2.24). Across its 52-week range of $0.81 to $4.60, IMNN sits at the 0.5% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.93).

IMNN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does IMNN pay a dividend and is it safe?

Imunon Inc. (IMNN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IMNN RQD Cockpit IMNN 12M Forecast IMNN Earnings & Move IMNN Dividends & DRIP IMNN Insiders & 13F IMNN Whale Options IMNN Profit Sankey IMNN News & Why